Literature DB >> 33606716

Pharmacological inhibition of catalase induces peroxisome leakage and suppression of LPS induced inflammatory response in Raw 264.7 cell.

Yizhu Mu1, Yunash Maharjan1, Raghbendra Kumar Dutta1, Xiaofan Wei1, Jin Hwi Kim1, Jinbae Son1, Channy Park1, Raekil Park1.   

Abstract

Peroxisomes are metabolically active organelles which are known to exert anti-inflammatory effects especially associated with the synthesis of mediators of inflammation resolution. However, the role of catalase and effects of peroxisome derived reactive oxygen species (ROS) caused by lipid peroxidation through 4-hydroxy-2-nonenal (4-HNE) on lipopolysaccharide (LPS) mediated inflammatory pathway are largely unknown. Here, we show that inhibition of catalase by 3-aminotriazole (3-AT) results in the generation of peroxisomal ROS, which contribute to leaky peroxisomes in RAW264.7 cells. Leaky peroxisomes cause the release of matrix proteins to the cytosol, which are degraded by ubiquitin proteasome system. Furthermore, 3-AT promotes the formation of 4HNE-IκBα adduct which directly interferes with LPS induced NF-κB activation. Even though, a selective degradation of peroxisome matrix proteins and formation of 4HNE- IκBα adduct are not directly related with each other, both of them are could be the consequences of lipid peroxidation occurring at the peroxisome membrane.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33606716      PMCID: PMC7894815          DOI: 10.1371/journal.pone.0245799

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  35 in total

1.  Plasmalogen phospholipids in plasma lipoproteins of normolipidemic donors and patients with hypercholesterolemia treated by LDL apheresis.

Authors:  C Bräutigam; B Engelmann; D Reiss; U Reinhardt; J Thiery; W O Richter; T Brosche
Journal:  Atherosclerosis       Date:  1996-01-05       Impact factor: 5.162

2.  Irreversible inactivation of catalase by 3-amino-1,2,4-triazole.

Authors:  D Darr; I Fridovich
Journal:  Biochem Pharmacol       Date:  1986-10-15       Impact factor: 5.858

Review 3.  Role of peroxisomes in ROS/RNS-metabolism: implications for human disease.

Authors:  Marc Fransen; Marcus Nordgren; Bo Wang; Oksana Apanasets
Journal:  Biochim Biophys Acta       Date:  2011-12-09

4.  Inhibition of NF-κB activation by 4-hydroxynonenal contributes to liver injury in a mouse model of alcoholic liver disease.

Authors:  Xiaobing Dou; Songtao Li; Zhigang Wang; Dongfang Gu; Chen Shen; Tong Yao; Zhenyuan Song
Journal:  Am J Pathol       Date:  2012-09-13       Impact factor: 4.307

5.  Progeric effects of catalase inactivation in human cells.

Authors:  Jay I Koepke; Christopher S Wood; Laura J Terlecky; Paul A Walton; Stanley R Terlecky
Journal:  Toxicol Appl Pharmacol       Date:  2008-06-24       Impact factor: 4.219

6.  A modified fixed staining method for the simultaneous measurement of reactive oxygen species and oxidative responses.

Authors:  Wan-Jou Shen; Chia-Yuan Hsieh; Chia-Ling Chen; Kao-Chi Yang; Ching-Ting Ma; Pui-Ching Choi; Chiou-Feng Lin
Journal:  Biochem Biophys Res Commun       Date:  2012-11-21       Impact factor: 3.575

7.  Catalase is required for peroxisome maintenance during adipogenesis.

Authors:  Yuuki Nitta; Sanae Muraoka-Hirayama; Koichi Sakurai
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2020-04-23       Impact factor: 4.698

8.  Peroxisome-generated hydrogen peroxide as important mediator of lipotoxicity in insulin-producing cells.

Authors:  Matthias Elsner; Wiebke Gehrmann; Sigurd Lenzen
Journal:  Diabetes       Date:  2010-10-22       Impact factor: 9.461

9.  The impact of peroxisomes on cellular aging and death.

Authors:  Selvambigai Manivannan; Christian Quintus Scheckhuber; Marten Veenhuis; Ida Johanna van der Klei
Journal:  Front Oncol       Date:  2012-05-21       Impact factor: 6.244

Review 10.  Does the Interdependence between Oxidative Stress and Inflammation Explain the Antioxidant Paradox?

Authors:  Subrata Kumar Biswas
Journal:  Oxid Med Cell Longev       Date:  2016-01-05       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.